VOXIMETRY
“Voximetry is delighted to support the important PDIB Project, which will build the infrastructure and operational foundations for dosimetry-guided radiopharmaceutical therapy (RPT) and help establish dosimetry as a valuable imaging biomarker. This project is well aligned with our aim to make routine dosimetry a reality for every RPT provider and patient worldwide.”
Novartis US
“Novartis is dedicated to enhancing cancer treatment for patients by integrating radiation therapy with precision medicine through radioligand therapies (RLT), already approved in multiple cancer settings.
Standardized radiation measurement at the site of the tumor is critically important as it enables healthcare providers to deliver RLT to cancer cells while minimizing exposure to healthy tissue in both community and academic settings.
We thank the FNIH for convening this crucial working group; we are confident that collaborating with other industry partners on this project will accelerate this critical research and the establishment of RLTs as a critical pillar of treatment for cancer patients in need.”
Eli Lilly and Company
“Lilly is committed to advancing the science of radiopharmaceuticals. This important initiative will bring greater standardization, precision, and innovation to the science of dosimetry, further enabling our work to advance meaningful radiopharmaceuticals for hard-to-treat cancers.”
Fusion Pharmaceuticals, A Member of the AstraZeneca Group
“Fusion Pharmaceuticals and AstraZeneca are pleased to participate in this important public-private partnership, which will help advance the field of radiopharmaceutical therapies. We look forward to helping establish industry benchmarks and standardized protocols that will enhance personalized dosimetry and contribute to safer and more effective treatments for patients worldwide.”
Perspective Therapeutics
“At Perspective Therapeutics, we are committed to advancing innovative treatments that improve patient outcomes. Radiopharmaceutical therapies hold immense potential to transform cancer care by offering targeted, effective, and less toxic treatments for patients. We are proud to partner on the PDIB project to help establish the critical infrastructure and standards needed to ensure accurate dosimetry and optimize treatment delivery. By collaborating with leaders in the field, we aim to accelerate the development and adoption of RPTs and ultimately improve survival rates and quality of life for patients worldwide.”
Capintec, a Mirion Medical Company
“Mirion Technologies, through our family of medically focused brands, is proud to support the FNIH Precision Dosimetry Imaging Biomarker (PDIB) project. This initiative represents a significant advancement in personalized radiation therapy, leveraging medical imaging to precisely measure radiation doses delivered to specific areas of the body. We are committed to applying our expertise in nuclear medicine and personalized dosimetry to enhance care and support the development of standardized methods and technologies in dosimetry-modulated radiopharmaceutical therapies.”
Hermes Medical Solutions
“We are proud to support the Biomarkers Consortium Precision Dosimetry Imaging Biomarker Project (PDIB). We welcome the initiative to develop a framework for development, standardization, and harmonization for quantitative RPT imaging and dosimetry. We will contribute to the project the best we can.”
ITM
“ITM is proud to support and participate in the FNIH Precision Dosimetry Imaging Biomarker (PDIB) Project, which aims to develop and test foundational, standardized methodologies supporting dosimetry-modulated targeted radiopharmaceutical therapy. This collaborative initiative complements ITM’s patient-centered vision and is essential to developing personalized radiopharmaceutical therapies.”
RayMed
“RayMed is deeply honored to join the Precision Dosimetry Imaging Biomarker (PDIB) consortium. Committed to driving innovation in radiopharmaceutical treatments, we aim to integrate cutting-edge technology and expertise to establish a standardized dosimetry framework, essential to the reliable clinical application of RPTs. Through our collaboration with PDIB, we will support precise RPT dosing and enhance dosimetry accuracy. Our ultimate goal is to enhance overall survival and improve the quality of life for cancer patients undergoing next-generation RPTs.”
RayzeBio, a Bristol Myers Squibb Company
“At RayzeBio, we believe that radiopharmaceutical therapies (RPT) represent a very promising new modality for cancer treatment, and through purposeful discovery and development, RPTs may offer therapeutic options that can deliver better outcomes for patients and their loved ones.
Through the Precision Dosimetry Imaging Biomarker project with the Foundation for the National Institutes of Health and other industry and academic partners, we believe we can advance efforts to create a framework that impacts the development of RPTs for patients worldwide.”
MIM Software, a GE HealthCare Company
“MIM Software, a GE HealthCare company, is thrilled to be a part of the FNIH P-DIB, which seeks to advance much-needed standardization in dosimetry calculation. Outcomes from this project shall be a key precursor to future high-quality clinical trials exploring dosimetry-modulated therapy, helping to realize the full potential of radiopharmaceutical therapies. This project aligns perfectly with MIM’s mission to maximize the benefit of personalized theranostic care.”